OS Therapies (OSTX) Total Debt (2023 - 2024)
OS Therapies' (OSTX) quarterly Total Debt came in at $250000.0 in Q2 2024, up 150.0% on a QoQ basis from $100000.0 in Q1 2024.
OS Therapies (OSTX) Total Debt (2023 - 2024) Analysis & Trends
OS Therapies (OSTX) has 2 years of Total Debt data on file, last reported at $250000.0 in Q2 2024.
- Quarterly Total Debt changed N/A year-over-year to $250000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $250000.0 (changed N/A YoY) and the FY2023 annual result came in at $1.4 million, changed N/A from the prior year.
- Total Debt rose to $250000.0 in Q2 2024, from $100000.0 in the prior quarter.
- In the past five years, Total Debt ranged from a high of $1.4 million in Q4 2023 to a low of $100000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 250,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 1.38 Mn |